CRL
Charles River Laboratories International, Inc.
Stock
$290.19+3.36 (+1.17%)Close Oct 2, 2026
- EBITDA, 2025
- $428M
- YoY, 2025
- −27.3%
- 5-year CAGR
- −8.5%
- 10-year CAGR
- +3.6%
EBITDA
EBITDA by fiscal year
| Period | EBITDA | YoY |
|---|---|---|
| 2025 | $428M | −27.3% |
| 2024 | $589M | −36.8% |
| 2023 | $931M | −2.5% |
| 2022 | $955M | +11.6% |
| 2021 | $855M | +28.1% |
| 2020 | $668M | +21.6% |
| 2019 | $549M | +11.4% |
| 2018 | $493M | +17.6% |
| 2017 | $419M | +15.2% |
| 2016 | $364M | +20.9% |
| 2015 | $301M | +9.9% |
| 2014 | $274M | +10.5% |
| 2013 | $248M | +0.4% |
| 2012 | $247M | −4.8% |
| 2011 | $260M | — |
| 2010 | −$205M | — |
| 2009 | $260M | — |
| 2008 | −$365M | — |